Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is among the cancer types with poorest prognosis and survival rates primarily due to resistance to standard-of-care therapies. including gemcitabine (GEM) and olaparib. Particularly. wild-type (wt)BRCA tumours. https://www.getpureroutine.com/